BioDelivery Sciences International Inc. entered into a definitive merger agreement for Collegium Pharmaceutical Inc. to purchase all outstanding shares of BDSI at $5.60 per share in an all-cash transaction.
EVERSANA and Noom announce strategic partnership to improve therapy adherence and patient engagement for complex therapies
Artificial Intelligence, Chronic Conditions, Cognitive Behavioral Therapy, Health Outcomes, Health Technology, Healthcare Communications Agencies, Life Sciences, Marketing & Advertising, Rare DiseasesEVERSANA and Noom announced a collaboration to increase medication adherence and improve health outcomes for the millions of patients suffering from chronic conditions and rare diseases worldwide.